Radiopharmaceutical Solutions Market

The global Radiopharmaceutical Solutions Market was valued at USD 6.6 billion in 2025 and is estimated at USD 7.3 billion in 2026. Revenue is projected to reach USD 16.8 billion by 2034, reflecting an 11.0% CAGR over 2026–2034.

The market encompasses medical radioactive tracers, isotope-containing preparations and targeted radionuclide medicines administered for nuclear medicine diagnosis or treatment. It includes technetium-99m diagnostic products, iodine-labelled agents, positron-emission tomography radiotracers and therapeutics such as lutetium-177 ligands. Revenue is assessed at the marketed radiopharmaceutical product level; raw isotopes embedded in those products are not counted twice.

Public company filings establish a substantial minimum commercial scale. Novartis reported 2025 sales of USD 1.994 billion for Pluvicto and USD 816 million for Lutathera, while Lantheus disclosed USD 989 million from PYLARIFY. Telix reported USD 621.9 million in precision-medicine revenue, mainly Illuccix and Gozellix. Together these in-scope disclosures exceed USD 4.4 billion before other diagnostic tracers, domestic radiopharmacies and smaller therapeutic brands are incorporated.

Growth is being influenced by regulatory extension of radionuclide therapy and the associated diagnostic imaging pathway. In March 2025, the FDA broadened Pluvicto use in selected metastatic castration-resistant prostate cancer, and on 31 July 2026 approved combination use in PSMA-positive metastatic androgen pathway modulation-na - ve or -sensitive disease. Expanded clinical eligibility can increase demand for matched diagnostic imaging and qualified treatment appointments.

Supply resilience shapes uptake. Technetium-99m derives from molybdenum-99 and cannot be stockpiled indefinitely, while fluorine-18 PET agents decay still faster. ANSTO reports isotope support for about 700,000 annual patient procedures in Australia; NRG PALLAS is replacing a major Dutch medical-isotope reactor. These manufacturing networks need backup logistics and local dispensing capacity to translate output into reliable patient appointments and finished-medicine revenue.

Source: Novartis FY2025 products; Lantheus FY2025 results; Telix FY2025 SEC filing; FDA July 2026 Pluvicto expansion.

This study measures worldwide manufacturer revenue from finished diagnostic and therapeutic radiopharmaceutical solutions, including radiolabeled PET and SPECT agents, kits and clinical radionuclide medicines. The analysis excludes imaging scanners, nonradioactive contrast material and downstream scan fees.

Radioligand label expansion supports therapy demand

The FDA extended Pluvicto into an earlier metastatic castration-resistant prostate cancer setting in March 2025, then approved combination treatment for PSMA-positive metastatic androgen pathway modulation-na - ve or -sensitive disease in July 2026. These clinical additions broaden the potential use of targeted lutetium therapy beyond its original population. They also require PSMA imaging for appropriate patient selection, supporting demand for companion tracers and nuclear-medicine referral pathways. Commercial conversion depends on approved local labels, specialized treatment bays and isotope delivery at the required scheduled activity.

Product sales validate a multi-billion-dollar marketplace

Novartis disclosed USD 1.994 billion of Pluvicto sales and USD 816 million of Lutathera in 2025. The diagnostic side includes Lantheus PYLARIFY revenue of USD 989 million and Telix precision-medicine revenue of USD 621.9 million, most from PSMA products. These amounts illustrate the sizeable value already attached to labeled diagnostic and treatment agents, but they do not cover routine hospital technetium services or every nuclear pharmacy. They also demonstrate why GE HealthCare’s broader USD 2.9 billion pharmaceutical diagnostics segment cannot be equated with radioactive tracers alone.

Isotope decay creates a structural distribution barrier

Technetium-99m has a physical half-life near six hours, making delivery depend on generators supplied with its longer-lived molybdenum-99 precursor. Fluorine-18 products require even tighter local routing from cyclotron facilities. NTP notes that Mo-99 itself decays over about 66 hours and cannot be accumulated as ordinary warehouse stock. A processing interruption therefore has an immediate clinical effect, including rescheduled patient imaging. Suppliers with redundant production, qualified distribution and predictable shipment timing can defend revenues despite alternative medical-isotope technologies.

Reimbursement and national appraisal limit realized access

The British NICE appraisal TA930 did not recommend Pluvicto for the specified advanced prostate cancer population in November 2023, even though the EMA had authorized the medicine. In June 2026 the EMA also described withdrawal of an application for a different earlier prostate cancer use, underscoring that U.S. expansions do not automatically transfer to Europe. Hospital purchasing budgets, radioprotection infrastructure and radionuclide tariffs influence affordability. The revenue implication is uneven rollout, with diagnostic PET reimbursement and specialty oncology funding shaping utilization separately.

Reactor renewal and local isotope production reduce interruption risk

NRG PALLAS started construction of its replacement reactor in September 2025 to maintain Dutch isotope output when the existing high-flux unit ages. India has reported domestic production of molybdenum-99, iodine-131 and lutetium-177, while China exported its first large-scale carbon-14 output in 2025. These developments can diversify sources of critical nuclides, but constructing new facilities requires regulatory approvals, shielded processing and trained staff. Suppliers must balance long-term capital investment against uncertain yield, maintenance costs and shifts toward accelerator-produced tracers.

Sources: Novartis; FDA; Lantheus; Telix; NTP; NICE; EMA; NRG PALLAS; India Department of Atomic Energy; CNNC.

Theranostics links diagnostic tracer volumes to therapy

PSMA-targeted diagnostic imaging determines eligibility for radioligand treatment, making paired tracer availability central to nuclear-medicine oncology. FDA decisions in 2025 and 2026 broadened the clinical Pluvicto population in distinct U.S. settings, while PSMA PET agents are increasingly differentiated on logistics and radiochemical formulation. Providers need imaging capacity, appropriate nuclear medicine interpretation and follow-on therapy scheduling. The opportunity is not a one-for-one correspondence between PET scans and drug infusions: not every imaged patient meets treatment criteria or receives all prescribed doses.

PET tracer competition accelerates formulation development

Lantheus reported PYLARIFY 2025 sales of USD 989 million, below the preceding year, in a market with more PSMA tracer choices. Its SEC filing notes a March 2026 FDA approval for PYLARIFY TruVu, designed to permit higher radioactive concentrations and potentially larger production batches. Competition can broaden provider choice and geographic availability while restraining net selling prices. The practical advantage of longer usable transport windows and efficient filling may determine which tracers gain share as imaging capacity extends beyond major tertiary centers.

New isotope supply capacity supports targeted oncology

The Belgian isotope organization IRE reported a January 2026 contract for shielded hot cells in a new radiopharmaceutical CDMO facility at Fleurus. Separately, its collaboration with SCK CEN targets Lu-177 supply and the firm has invested in germanium-68 production for gallium generators. Such projects show the shift from selling bulk reactor nuclides toward sophisticated processing and contract manufacturing. Revenue opportunities broaden into specialized labeling, quality-control services and products tailored to short-lived therapeutic or PET radionuclides.

Domestic nuclear-medicine systems grow across Asia

China’s CNNC exported commercial reactor-produced carbon-14 in September 2025 after scaling production at Qinshan, and Indian government disclosures document greater Lu-177 output in the 2025–26 fiscal year. Japan approved Pluvicto and its imaging selection agent Locametz in September 2025. Collectively these milestones expand the number of countries with production or licensed clinical pathways, although self-sufficiency does not ensure equal patient access. Product uptake still relies on quality validation, trained nuclear-medicine specialists and reimbursement for specialized oncology scans.

Distribution networks adapt to the physical half-life

Saudi Arabia’s King Faisal Specialist Hospital introduced air shipment of short-lived radiopharmaceuticals in January 2026 after obtaining aviation authority permission, drawing on a program that had supplied more than 800,000 patient doses historically. Air transport widens the effective radius of a central cyclotron or radiopharmacy when ground delivery would consume too much of a product’s useful activity. Logistics can therefore be a commercially meaningful substitute for building a full production unit in every city, provided chain-of-custody and radiological rules remain satisfied.

Nuclear-medicine medicines combine radionuclide physics, clinically targeted molecules and tightly controlled preparation. The isotope determines energy and half-life; the ligand, antibody or kit directs distribution in the body. Commercial advantages arise where the full chain from production to safe patient administration remains reliable.

Production routes vary materially. Tc-99m comes from a Mo-99 generator with recurring replenishment; several PET tracers are cyclotron-produced and distributed rapidly; therapeutic Lu-177 can rely on reactor-derived material and radiochemical labeling. Each route requires radionuclidic purity, sterility controls, certified radiation transport and medical staff trained for handling radioactive products. These constraints support specialized suppliers but create cost and wastage risks when appointments are delayed.

Theranostics uses imaging and treatment agents linked by a biological target. A PSMA PET scan can identify whether a patient’s tumor distribution is suitable for targeted therapy, but not every patient qualifies under current labels. Companies selling imaging agents may benefit from expanded therapeutic use even without marketing the treatment drug. The causal link is stronger than a simple rise in general cancer incidence because uptake depends on specific biomarker-guided treatment pathways.

Novel alpha-emitting isotopes and improved PET labeling platforms are under development, while the commercial market still relies on established technetium and selected radioligand products. IRE’s Belgian isotope projects and Japan’s 2025 approval of Pluvicto with Locametz signal a continuing need for domestic production and coordinated regulation. Evidence of installed capacity should not be interpreted as immediate product revenue until reliable clinical batches are actually delivered.

The type split organizes this market by delivered product use and actual clinical purchasing behavior. This type classification follows the commercial dose actually supplied and avoids double-counting overlapping clinical pathways.

Across type segments, demand growth will be tested by isotope availability, regulatory approval, provider capacity and reimbursement rather than simply by the number of imaging facilities. The type outlook balances stronger proprietary oncology sales against continued demand for more familiar diagnostic products and dependable dose shipment.

The application split organizes this market by delivered product use and actual clinical purchasing behavior. This application classification follows the commercial dose actually supplied and avoids double-counting overlapping clinical pathways.

Across application segments, demand growth will be tested by isotope availability, regulatory approval, provider capacity and reimbursement rather than simply by the number of imaging facilities. The application outlook balances stronger proprietary oncology sales against continued demand for more familiar diagnostic products and dependable dose shipment.

The end user split organizes this market by delivered product use and actual clinical purchasing behavior. This end user classification follows the commercial dose actually supplied and avoids double-counting overlapping clinical pathways.

Across end user segments, demand growth will be tested by isotope availability, regulatory approval, provider capacity and reimbursement rather than simply by the number of imaging facilities. The end user outlook balances stronger proprietary oncology sales against continued demand for more familiar diagnostic products and dependable dose shipment.

The delivery method split organizes this market by delivered product use and actual clinical purchasing behavior. This delivery method classification follows the commercial dose actually supplied and avoids double-counting overlapping clinical pathways.

Across delivery method segments, demand growth will be tested by isotope availability, regulatory approval, provider capacity and reimbursement rather than simply by the number of imaging facilities. The delivery method outlook balances stronger proprietary oncology sales against continued demand for more familiar diagnostic products and dependable dose shipment.

Regional commercialization is shaped by payer decisions, locally licensed drugs, reactor or cyclotron supply, delivery time and specialist nuclear-medicine capacity. The five regions are assessed using verifiable national developments, without dividing modeled revenue into unsupported country sales figures.

Market access in nuclear medicine is the combination of payment for clinically warranted imaging or treatment, physical radionuclide supply and licensed staff or facilities. A radiopharmaceutical with national authorization may still be unavailable if a hospital cannot obtain a timely dose or the payer does not fund its use.

The economic unit differs sharply between a reactor-produced diagnostic precursor and a proprietary targeted cancer therapy. Routine SPECT care uses frequent but relatively low-unit-value generator and kit supplies, while a Lu-177 therapy involves sophisticated targeting chemistry, specialist handling and repeated scheduled doses. Payers reimburse these services through distinct hospital, drug and imaging pathways. Conflating them would distort market size and predict procedure growth poorly.

Lantheus’s 2025 SEC report discussed separate payment for selected expensive diagnostic radiopharmaceuticals within the U.S. hospital outpatient Medicare system. That payment policy can influence access to advanced PET agents but should not be generalized to every radioactive medicine or every clinical site. In England, NICE’s negative 2023 appraisal underscores how national treatment value assessments can block routine financing despite authorization and evidence of international use.

Physical isotope availability imposes another gate. NRG PALLAS reactor replacement, ANSTO Mo-99 processing and Saudi air transport reflect different approaches to stable supply: redundant core infrastructure, local licensed manufacture and wider distribution radius. Each can improve the odds that a required dose reaches a patient on schedule. However, these investments require ongoing operating approvals, technical staff and quality control before they materially add recognized manufacturer revenue.

Source: Lantheus 2025 SEC filing; NICE TA930; NTP reactor isotope process.

Regulatory milestones are distinct for a radiopharmaceutical drug, its diagnostic selection agent and its manufacturing infrastructure. The market combines changes in approved clinical populations with a parallel pipeline of isotope production, formulation and distribution projects.

In the United States, the 2026 Pluvicto indication expansion is specific to PSMA-positive metastatic disease in a hormonal treatment setting and requires appropriate imaging selection. The April 2024 pediatric Lutathera decision applied to certain somatostatin-receptor-positive neuroendocrine tumors. These authorizations support different product franchises and patient pathways and should not be generalized to all nuclear-medicine procedures.

The EMA’s June 2026 communication on Novartis withdrawing a requested change for Pluvicto means that the relevant earlier-line European population should not be treated as already covered by that withdrawn application. Japan’s September 2025 authorizations provide a separate example of successful national review for therapy and associated imaging. Forecasts must therefore reflect the territorial timing of approvals and national payer decisions.

On the manufacturing side, reactor refurbishment, isotope-separation processes and cyclotron investments can take years to produce commercially usable batches. NRG PALLAS and IRE projects illustrate capacity efforts, while Chinese carbon-14 exports and Brazil’s Lu-177 initiative document expanded domestic capability. For isotope suppliers, project execution and quality certification will be essential to converting these developments into reliable finished-product sales.

The competitive landscape spans three positions: high-value finished-drug developers, commercial diagnostic-tracer manufacturers and upstream isotope or radiopharmacy suppliers. Public sales disclosures are strongest for Novartis, Lantheus and Telix. NRG PALLAS, NTP, ANSTO, CNNC, IRE, Nordion and POLATOM participate in the supply chain but cannot have all precursor shipments added to downstream product sales.

GE HealthCare operates a sizeable pharmaceutical-diagnostics business but the reported USD 2.9 billion segment includes nonradioactive contrast media, so using the entire segment as radiopharmaceutical sales would materially overstate the relevant boundary. Other clinical participants include Curium, Eckert & Ziegler and BWXT in finished tracers, radiochemistry or isotope supply. Their commercial role varies by geographic license, manufacturing route and the extent of downstream branded-drug participation.

The long-run competitive advantage rests on clinical authorization, production yield, product availability and trusted distribution. Major therapeutic brands benefit from protected clinical evidence and specialized patient selection, while routine isotope suppliers compete partly on service reliability. New reactors and cyclotrons could improve resilience, but capex needs and isotope half-lives preserve significant operational risk. Reliable isotope supply remains distinct from successful clinical commercialization, which also requires reimbursement, specialist staffing and authorized preparation sites.

• Novartis AG
• Lantheus Holdings, Inc.
• Telix Pharmaceuticals Limited
• Curium Pharma
• GE HealthCare Technologies Inc.
• Cardinal Health, Inc.
• Eckert & Ziegler SE
• Jubilant Pharmova Limited
• Bayer AG
• Bracco Imaging S.p.A.
• IBA SA
• Cyclomedica Australia Pty Ltd
• Sotera Health / Nordion
• Actinium Pharmaceuticals Inc.

Radiopharmaceutical sales are projected to rise from USD 7.3 billion in 2026 to USD 16.8 billion in 2034, equivalent to an 11.0% CAGR. The outlook weighs growth in higher-value radionuclide oncology against stable conventional diagnostic use, pricing pressure in tracer competition and the operational constraints of short-lived isotope supply.

Growth in the early forecast years will be driven by already marketed nuclear oncology products and the size of the patient pool meeting country-specific labels. U.S. Pluvicto expansions provide a more direct revenue catalyst than speculative pipeline products because the therapy already has an established supply and treatment network. Further commercial adoption depends on referral coordination, identifying eligible patients promptly, and securing protected administration capacity rather than merely installing more diagnostic scanners.

The mid-period outlook reflects investment in stable upstream production. New reactor capacity in the Netherlands, isotope expansion in China and India, and increased processing capability in Belgium could improve supply reliability. These efforts need licensing, commissioning and specialized staff; they are not equivalent to instantaneous market expansion.

Adoption differs sharply across health systems. NICE’s earlier Pluvicto recommendation and the EMA’s withdrawn application demonstrate that European market access cannot be inferred from U.S. FDA decisions. Japan’s approval of therapy alongside Locametz creates a specific clinical route, while emerging markets require investment in radiopharmacies and radiation-authorized centers.

Growth in procedures and dollar sales will diverge. A rise in PET examinations can increase radiotracer volumes while competition compresses prices; conversely, a smaller increase in radionuclide cancer treatment may have a larger value effect per dose. The model excludes the full GE HealthCare contrast business and avoids re-adding upstream radioisotope input costs already embedded in finished pharmaceutical revenue. Demand and equipment capacity still vary with hospital budgets and workforce availability.

The report covers commercial radionuclide products for imaging and treatment, with explicit boundaries between drug revenues, upstream isotope ingredients and radiology services.